Drug Trial Radar · NCT07355218
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
202
Planned (sponsor's estimate)
Start
Apr 1, 2026
Primary completion
May 25, 2029
Study completion May 25, 2029
Sponsor
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- Jan 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration: Up to 35 weeks. Treatment Duration: 24 weeks. Visit Frequency: every 4 weeks, with the exception of the Week 2 televisit. Study Intervention Name: Enpatoran, Placebo. Intervention Form: Film-coated tablet.
Conditions
- Systematic Lupus Erythematosus
- Cutaneous Lupus Erythematosus
Interventions
EnpatoranDrug
Participants will receive a dose of Enpatoran orally twice daily from Day 1 to Day 168.
PlaceboDrug
Participants will receive a single oral dose of a placebo matching Enpatoran tablet twice daily from Day 1 to Day 168.
Standard of care (SoC)Drug
Participants will receive Investigator-recommended SoC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) 70 Response, Defined as >= 70 Percent (%) Decrease in CLASI-A Score From BaselineTime frame: At Week 24
Locations
70 sites in 20 countries. Site status is shown where the registry gives one.
Inland Rheumatology Clinical Trials, Inc.
Upland, California · Recruiting
Omega Research Debary, LLC
DeBary, Florida · Recruiting
Centre for Rheumatology, Immunology and Arthritis
Fort Lauderdale, Florida · Recruiting
South Florida Rheumatology
Hollywood, Florida · Recruiting
GTL Medical And Research Group
Miami, Florida · Recruiting
Bolanos Clinical Research
Pembroke Pines, Florida · Recruiting
Vantage Clinical Trials
Tampa, Florida · Recruiting
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana · Recruiting
Accurate Clinical Research Inc. - Lake Charles
Lake Charles, Louisiana · Recruiting
Oakland Hills Dermatology
Auburn Hills, Michigan · Recruiting
Arthritis and Osteoporosis Consultants of the Carolinas II, LLC
Charlotte, North Carolina · Recruiting
Superior Clinical Research, LLC
Smithfield, North Carolina · Recruiting
North Texas Center for Clinical Research
Frisco, Texas · Recruiting
Prolato Clinical Research Center
Houston, Texas · Recruiting
Accurate Clinical Research
Humble, Texas · Recruiting
Monash Medical Centre Clayton
Clayton, Victoria, Australia · Recruiting
Universitair Ziekenhuis Gent - UZG
Ghent, Belgium · Recruiting
Hospital Alemão Oswaldo Cruz
São Paulo, Brazil · Recruiting
RDSS Ricardo Diaz Scientific Solution
São Paulo, Brazil · Recruiting
L2IP - Instituto de Pesquisas Clínicas Ltda.
Brasília, Federal District, Brazil · Recruiting
A2Z Clinical Centro Avancado de Pesquisa Clinica
Campinas, São Paulo, Brazil · Recruiting
DCC 1 Sevlievo EOOD
Sevlievo, Bulgaria · Recruiting
DCC "Alexandrovska", EOOD
Sofia, Bulgaria · Recruiting
The Medical Arts Health Research Group - 300128547
Kelowna, British Columbia, Canada · Recruiting
Fujian Provincial Hospital
Fuzhou, Fujian, China · Recruiting
Nanfang Hospital of Southern Medical University - 300165627
Guangzhou, Guangdong, China · Recruiting
The Second Hospital of Hebei Medical University - 300184836
Shijiazhuang, Hebei, China · Recruiting
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China · Recruiting
The First Affiliated Hospital of Baotou Medical College
Baotou, Inner Mongolia, China · Recruiting
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China · Recruiting
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
The First Hospital of Jilin University
Changchun, Jilin, China · Recruiting
Qilu Hospital of Shandong University - 300163463
Jinan, Shandong, China · Recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, China · Recruiting
Fakultni nemocnice u sv. Anny v Brne - Dept of I. Dermatovenerologicka klinika
Brno, Czechia · Recruiting
Prof.MUDr.Petr Arenberger,DrSc.MBA
Prague, Czechia · Recruiting
MEDICAL PLUS s.r.o.
Uherské Hradiště, Czechia · Recruiting
Universitaetsklinikum Tuebingen - Hautklinik
Tübingen, Baden-Wurttemberg, Germany · Recruiting
Klinikum Oldenburg AoeR - Universitatsklinik f Dermatologie u. Allergologie
Oldenburg, Lower Saxony, Germany · Recruiting
Helios Klinikum Wuppertal - Klinik fuer Dermatologie, Venerologie
Wuppertal, North Rhine-Westphalia, Germany · Recruiting
Showing 40 of 70 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.